<u>Clayton R. Polowy, M.D.</u> Ironwood Cancer and Research Centers Division of Oncology and Hematology

Breast Malignancies

Education:	
08/01/2001-06/01/2004	Rush Presbyterian-St. Luke's Medical Center
	Chicago, IL
	Fellowship in Hematology/Oncology
	Chief Fellow, 2003-2004
08/01/1998-06/01/2001	Rush Presbyterian-St. Luke's Medical Center
	Chicago, IL
	Residency in Internal Medicine
08/01/1994-06/01/1998	State University of New York at Buffalo
	Buffalo, NY
	Doctor of Medicine
08/01/1990-06/01/1994	Miami University
	Oxford, OH
	Bachelor of Arts in Biological Science
Professional Experience:	

Professional Experience:

1/2012 – Present	Physician, Ironwood Cancer & Research Centers, Mesa, AZ
08/2004-12/2011	Physician, Desert Oncology Associates, Mesa, AZ

Activities and Honors:

Certifications:

American Board of Internal Medicine- Oncology American Board of Internal Medicine

<u>Awards, Honors and Committees:</u> PHOENIX Magazine Top Doctor Award Vice Chair Dept of Internal Medicine, Banner Desert Medical Center, 2006 Top Physician Award, Adult Acute Care Services Banner Desert Medical Center-2006 WOW! Award Outstanding Service as Fellow Bone Marrow Transplant Service, Rush Presbyterian-St. Luke's Medical Center-2003

Professional Memberships:

American Medical Association Leukemia Society of America, Illinois Chapter American Lung Association, Chicago Thoracic Society

Publications:

ABSTRACTS Non-small cell lung cancer patients with undetectable epidermal growth factor receptor (EGFR) expression respond poorly to ZD1839 (Iressa). C. Polowy, J Coon, W Leslie, L DiNunno, I Lukie, G Kanevsky, M Gayle, L Morrison, S Seelig, P Bonomi.
Poster Presentation, 10th World Conference on Lung Cancer Vancouver, BC August 14, 2003

Predictive value of EGFR levels by FISH and IHC in NSCLC patients treated with ZD1839 (Iressa). **C Polowy,** J Coon, W Leslie, L DiNunno, I Lukie, G Kanevsky, M Gayle, L Morrison, S Seelig, P Bonomi.

Proc Am Soc Clin Oncol 2003. Abstract No. 2845

Overexpression of E2F1 Target Gene-DHFR in Hypoplastic Myelodysplasia. B Dangerfield, S Mundle, **C Polowy,** B Mativi, V Shetty, S Alvi, C Menon, M Ekbal, S Dar, E Broderick, P Venugopal, S Gregory, A Raza. *Proc Am Soc Clin Oncol 2000.* Abstract No. 2597

Research Trials:

Sub investigator in Ironwood Cancer and Research Centers trials, please refer to website for details.